Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.

被引：0

作者：

Usmani, Saad Zafar

Karlin, Lionel

Benboubker, Lotfi

Nahi, Hareth

San-Miguel, Jesus

Trancucci, Danielle

Qi, Keqin

Stephenson, Tara

Perales-Puchalt, Alfredo

Chastain, Katherine

Chari, Ajai

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Ctr Hosp Lyon Sud, Lyon, France

[3] Ctr Hosp Reg Univ, Hop Bretonneau, Tours, France

[4] Karolinska Univ Hosp Huddinge, Stockholm, Sweden

[5] Univ Navarra, Pamplona, Spain

[6] Janssen Res & Dev, Raritan, NJ USA

[7] Janssen Res & Dev, Titusville, NJ USA

[8] Janssen Res & Dev, Spring House, PA USA

[9] Mt Sinai Sch Med, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8034

引用

页数：1

共 50 条

[31] Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).
van de Donk, Niels W. C. J.
Garfall, Alfred L.
Benboubker, Lotfi
Uttervall, Katarina
Groen, Kaz
Rosinol, Laura
Matous, Jeffrey V.
Vishwamitra, Deeksha
Hodin, Caroline
Stephenson, Tara
Qi, Keqin
Zuppa, Athena
Chastain, Katherine
Mateos, Maria-Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[32] Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study.
Hungria, Vania T. M.
San Miguel, Jesus F.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios A.
Elghandour, Ashraf
Jedrzejczak, Wieslaw W.
Guenther, Andreas
Nakorn, Thanyaphong Na
Siritanaratkul, Noppadol
Schlossman, Robert L.
Hou, Jian
Moreau, Philippe
Lonial, Sagar
Lee, Jae Hoon
Einsele, Hermann
Sopala, Monika
Bengoudifa, Bourras-Rezki
Corrado, Claudia
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[33] Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca I.
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S25 - S26
[34] Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels
Moreau, Philippe
Garfall, Alfred
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay
Martin, Thomas
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S478
[35] MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Touzeau, Cyrille
Hungria, Vania T. M.
Bhutani, Divaya
Landgren, Ola
Vieyra, Diego
Guo, Yue
Verona, Raluca
Miao, Xin
Qi, Mia
Watkins, Latisha
Shah, Priya
Chastain, Katherine
Qi, Ming
Quach, Hang
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita Y.
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] Long-term follow-up from MajesTEC-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Donk, Van De N. W.
Moreau, P.
Garfall, A. L.
Bhutani, M.
Oriol, A.
Nooka, A. K.
Martin, T. G.
Rosinol, L.
Mateos, M. -V.
Bahlis, N.
Popat, R.
Besemer, B.
Lopez, Martinez J.
Krishnan, A.
Delforge, M.
Trancucci, D.
Verona, R., I
Stephenson, T.
Chastain, K.
Sidana, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 124 - 124
[38] Brazilian Relapsed Refractory Multiple Myeloma Patients Treated with Teclistamab Outside of Clinical Trials as an Expanded Access Program
Pericole, Fernando
Lima, Juliana Souza
Ottoni, Erica
Ribeiro, Glaciano
Crusoe, Edvan de Queiroz
Cunha, Rafael
Costa, Abel
Cury, Priscilla
Maciel, James
Hungria, Vania T. M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S196 - S197
[39] Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy
Grajales-Cruz, Ariel F.
Castaneda, Omar
Hansen, Doris K.
Vazquez-Martinez, Mariola A.
Blue, Brandon
Khadka, Sushmita
Liu, Hien
Ochoa-Bayona, Jose L.
Freeman, Ciara Louise L.
Locke, Frederick L.
Nishihori, Taiga
Shain, Kenneth
Baz, Rachid
Alsina, Melissa
BLOOD, 2023, 142
[40] Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study.
Jakubowiak, Andrzej J.
Benson, Don M., Jr.
Bensinger, William
Siegel, David S.
Zimmerman, Todd M.
Mohrbacher, Ann
Richardson, Paul G.
Afar, Daniel E. H.
Singhal, Anil K.
Anderson, Kenneth C.
BLOOD, 2010, 116 (21) : 1245 - 1245

← 1 2 3 4 5 →